Matt Jacobsen

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome

Gabriel Balmus, Delphine Larrieu, Ana C. Barros et al. · Nature Communications · 2018 · 217 citations · Full text

Education, Genetics, Molecular Biology +17

Synthetic lethality between PAXX and XLF in mammalian development

Gabriel Balmus, Ana C. Barros, Paul W.G. Wijnhoven et al. · Genes & Development · 2016 · 90 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Histopathologic Features, Immunophenotyping, Clonality, and Eubacterial Fluorescence In Situ Hybridization in Cats With Lymphocytic Cholangitis/Cholangiohepatitis

Amy L. Warren, Sean P. McDonough, Ruthanne Chiotti et al. · Veterinary Pathology · 2010 · 70 citations

Medicine, Pathology, Veterinary Pathology +15

Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers

Timothy Schulz-Utermoehl, Sunil Sarda, John R. Foster et al. · Xenobiotica · 2011 · 33 citations

Pharmacy, Pharmacokinetics, Pharmacology +17